Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study

INTRODUCTION: Subsequent lines of subcutaneous tumor necrosis factor alpha inhibitor (SC-TNFi) treatment may be well motivated in the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)—collectively named inflammatory arthritis (IA). However, the costs...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalén, Johan, Luttropp, Karin, Svedbom, Axel, Black, Christopher M., Kachroo, Sumesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444358/
https://www.ncbi.nlm.nih.gov/pubmed/32647910
http://dx.doi.org/10.1007/s12325-020-01425-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444358/
https://www.ncbi.nlm.nih.gov/pubmed/32647910
http://dx.doi.org/10.1007/s12325-020-01425-8

Ejemplares similares